The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis.

Abstract

Axial SpA patients failure to respond to TNF-α blockers may be at least partially related to immunogenicity. Measurement of anti-drug antibodies and drug levels in these patients may assist in determining further treatment strategies.